In this article, we will discuss Anlotinib (Background-8). So, let’s get started.
Preclinical studies have shown that anlotinib inhibits cell migration and the formation of capillary-like tubes induced by VEGF/PDGF-BB/FGF-2 in endothelial cells.
Furthermore, anlotinib significantly suppressed VEGF/PDGF-BB/FGF-2-induced angiogenesis in vitro and in vivo.
Research into possible mechanisms indicated that anlotinib inhibits the activation of VEGFR2, PDGFRβ, and FGFR1, as
well as downstream ERK signaling. The anti-angiogenic activity of anlotinib is stronger than that of three other anti-angiogenesis drugs, including sunitinib, sorafenib, and nintedanib.